ACTG 5279 Phase III Clinical Trial of Ultra-Short-Course Rifapentine/Isoniazid for the Prevention of Active Tuberculosis in HIV-Infected Individuals with Latent Tuberculosis Infection
ACTG 5290: A Randomized, Phase 2b Study of a Double-Dose Lopinavir/Ritonavir-Based Antiretroviral Regimen with Rifampin-Based Tuberculosis Treatment versus a Standard-Dose Lopinavir/Ritonavir-Based Antiretroviral Regimen with Rifabutin-Based Tuberculosis Treatment with or without Raltegravir in HIV-1-Infected Persons Requiring Treatment for Active TB and HIV
ACTG 5295: Evaluation of Xpert MTB/RIF Assay for the Rapid Identification of TB and TB Rifampin Resistance in HIV-Infected and HIV-Uninfected Pulmonary Tuberculosis Suspects
ACTG 5302: BioBank for Surrogate Marker Research for TB (B-SMART), A Multicenter Trial of the AIDS Clinical Trials Group (ACTG) in Collaboration with the Tuberculosis Trials Consortium (TBTC)
ACTG 5306: A Phase I, Three-Arm Safety, Tolerability, and Pharmacokinetic Interaction Study of PA-824, an Investigational Nitroimidazole for the Treatment of Tuberculosis, together with Efavirenz, Ritonavir-Boosted Lopinavir, or Rifampin
ACTG 5307: A Randomized Phase IIa Clinical Trial Comparing the Early Bactericidal Activity (EBA) of a Standard Anti-Tuberculosis Regimen (RHZE) with a Regimen Omitting Isoniazid (RZE) or a Regimen Substituting Moxifloxacin for Isoniazid (RMZE) During Days 3 to 14 of Tuberculosis Therapy
ACTG 5311: Phase I Clinical Trial of the Pharmacokinetics of High-dose Daily Rifapentine, Given as a Single Dose or in Divided Doses to Healthy Volunteers
Prospective, randomized, double-blinded trial of the efficacy and toxicity of a regimen for MDR-TB treatment containing one new agent
Prospective, randomized, open label trial of the efficacy and toxicity of a regimen for MDR-TB treatment containing two new agents
TBTC Study 33: An Evaluation of Adherence to Latent Tuberculosis Infection (LTBI) Treatment With 12 Doses of Once Weekly Rifapentine (RPT) and Isoniazid (INH) Given as Self-administered (SAT) Versus Directly-observed Therapy (DOT): iAdhere
